daridorexant; nemorexant (Quviviq)

^[1]^[2]^[3]^[4]^[5]

Indications

* comorbidities that interfere with sleep such as obstructive sleep apnea, restless legs syndrome, excessive caffeine use, & prolonged daytime naps have not been studied

5, 10, 25, or 50 mg

↑ ^1.0 ^1.1 Dauvilliers Y, Zammit G, Fietze I et al. Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. Ann Neurol 2020 Mar; 87:347. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31953863 https://onlinelibrary.wiley.com/doi/full/10.1002/ana.25680
↑ ^2.0 ^2.1 Zammit G, Dauvilliers Y, Pain S, et al. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology 2020 May 26; 94:e2222 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32341187 https://n.neurology.org/content/94/21/e2222
↑ Greb E FDA OKs New Adult Insomnia Med. Medscape. January 10, 2022 https://www.medscape.com/viewarticle/966295
↑ Mignot E, Mayleben D, Fietze I et al Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurology. 2022. Volume 21, ISSUE 2, P125-139, Feb 1. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35065036 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00436-1/fulltext
↑ Medscape: daridorexant (Rx) https://reference.medscape.com/drug/quviviq-daridorexant-4000202